实体瘤治疗新策略:嵌合抗原受体巨噬细胞的免疫治疗潜力  

A new strategy for solid tumor treatment:the immunotherapeutic potential of chimeric antigen receptor macrophages

作　　者：孔庆浩 李爽 陆荫英[1] Kong Qinghao;Li Shuang;Lu Yinying(The Second Clinical Medical College of Anhui Medical University,Hefei 230022,Anhui,China;Department of Liver Diseases,The Fifth Medical Center of Chinese People's Liberation Army General Hospital,Beijing 100039,China;Peking University 302 Clinical Medical School,Beijing 100039,China)

机构地区：[1]安徽医科大学第二临床医学院,安徽合肥230022 [2]解放军总医院第五医学中心肝病医学部,北京100039 [3]北京大学三〇二临床医学院,北京100039

出　　处：《肝癌电子杂志》2024年第3期16-19,共4页Electronic Journal of Liver Tumor

摘　　要：实体瘤是当今世界严重威胁人类健康的疾病之一。针对实体瘤的治疗方法,传统手术、放射治疗、化学药物治疗存在自身的局限性,免疫检查点抑制剂虽有效,但并非所有患者均有响应。嵌合抗原受体-巨噬细胞(chimeric antigen receptor-macrophage, CAR-M)疗法是通过基因工程改造巨噬细胞,使其表达特异性识别肿瘤抗原的嵌合受体,展现出定向杀伤肿瘤细胞的潜力。但目前CAR-M治疗实体瘤领域还处于临床前和早期临床研究阶段。本文将对CAR-M目前已进行的前期研究现状进行全面综述,包括CAR结构的设计、供体细胞来源及CAR基因向巨噬细胞的载体递送等方面,并对目前CAR-M发展的局限性和挑战进行汇总,为未来CAR-M的发展提供新的研究思路。Solid tumors are one of the major diseases threatening human health worldwide.Traditional treatments such as surgery,radiotherapy,and chemotherapy have their inherent limitations,and although immune checkpoint inhibitors have shown efficacy,not all patients respond to them.Chimeric antigen receptor-macrophage(CAR-M)therapy involves the genetic engineering of macrophages to express chimeric receptors that specifically recognize tumor antigens,demonstrating the potential for targeted tumor cell destruction.However,CAR-M therapy for solid tumors is currently in the preclinical and early clinical research stages.This paper provides a comprehensive review of the current state of preclinical studies on CAR-M,including the design of CAR structures,sources of donor cells,and vectors for delivering CAR genes to macrophages.Additionally,it summarizes the limitations and challenges faced in the development of CAR-M,offering new research perspectives for the future advancement of CAR-M therapy.

关 键 词：嵌合抗原受体 巨噬细胞 肿瘤相关巨噬细胞 实体瘤 

分 类 号：R730.51[医药卫生—肿瘤]